secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001711279-23-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients
--------------------------------------------------------------------------------

- DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.
- RDEB patient's wound burden decreased 80-90%, reverted from severe to intermediate generalized phenotype.
- No significant adverse events attributed to B-VEC; treatment well tolerated.
- RDEB patient showed systemic improvements: increased height, weight, and serum albumin levels.
- Data presented at ISID meeting in Tokyo, May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/0001711279-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000033/krys-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer